Tesamorelin is a stabilized, 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), modified with a hexenoyl group that gives it greater resistance to enzymatic breakdown than unmodified GHRH fragments. Helix Bio supplies tesamorelin acetate as a lyophilized research compound for laboratory study of GHRH receptor activity and the growth hormone axis. This listing is for a research chemical only. Tesamorelin also exists as an FDA-approved prescription drug (marketed as Egrifta / Egrifta WR) for a specific clinical indication, but that is a separate, pharmacy-dispensed product manufactured under a New Drug Application. Helix Bio's research-use-only tesamorelin is not that product, is not equivalent to it, and is not sold, labeled, or intended for human or animal use, self-treatment, or off-label use of any kind.
HPLC certified
Independent analysis
Highest standard
Full traceability
Tesamorelin was approved by the FDA in 2010 (originally under the brand Egrifta, now available as Egrifta WR) for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy, and it remains an actively prescribed, pharmacy-dispensed medication in the United States, manufactured by Theratechnologies. Separately, tesamorelin acetate is also manufactured and sold as a research-use-only (RUO) compound for laboratories studying GHRH receptor pharmacology, peptide stability, and the growth hormone axis. Helix Bio's product is the RUO research compound, not the approved pharmaceutical.
Tesamorelin consists of the 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue — a modification designed, per the compound's published pharmacology, to slow enzymatic degradation compared with unmodified GHRH fragments. Helix Bio's tesamorelin is supplied as the acetate salt, in lyophilized powder form. The free-base compound is identified by CAS number 218949-48-5 (acetate salt: CAS 901758-09-6), with a molecular formula of C221H366N72O67S and a free-base molecular weight of approximately 5,135.9 g/mol.
This product exists to support in vitro and in vivo laboratory research into GHRH receptor signaling, peptide stability engineering, and endocrine regulation. It is manufactured for controlled research settings and is not formulated, tested, or approved by Helix Bio for therapeutic, diagnostic, cosmetic, or any other human or veterinary use.
Researchers comparing tesamorelin sources are usually weighing documentation and sourcing transparency, not marketing claims. Helix Bio's listing is built around a clearly identified compound (CAS 218949-48-5), a stated acetate salt form, and packaging built for laboratory handling rather than consumer retail. Because tesamorelin already has a well-documented FDA-approved reference product, researchers have an unusually clear benchmark to compare purity and identity claims against — which makes accurate, unembellished specification data more valuable here than in categories without an approved reference compound.
This product is not intended for individual consumers, is not a supplement or over-the-counter product, and is not a substitute for the FDA-approved pharmaceutical (Egrifta / Egrifta WR), which is available only through a prescription and pharmacy dispensing channel. It is not intended for personal, human, or veterinary use.
| Field | Detail |
|---|---|
| Product Name | Tesamorelin Acetate |
| Category | Stabilized GHRH Analog / Research Peptide |
| CAS Number | 218949-48-5 (free base); 901758-09-6 (acetate salt) |
| Molecular Formula | C221H366N72O67S |
| Molecular Weight | ≈ 5,135.9 g/mol (free base) |
| Sequence | 44-amino-acid GHRH analog with N-terminal hexenoyl modification |
| Purity | Confirm against current Certificate of Analysis |
| Appearance | White to off-white lyophilized powder |
| Storage (unreconstituted) | Store frozen and desiccated, per current COA |
| Packaging | Sealed research vial |
| Research Use | Laboratory research only — not for human or animal use; not the FDA-approved pharmaceutical product |
| Manufacturer / Source | Helix Bio |
| Quality Documentation | Confirm current COA availability and lot-testing process |
Published literature and regulatory filings on tesamorelin span several research areas relevant to laboratories working with this compound:
This is a summary of research directions reflected in published and regulatory literature, not a claim of efficacy, safety, or suitability for any application outside a controlled laboratory setting, and not a substitute for information about the FDA-approved pharmaceutical form. It is not medical, dosing, or treatment information.
Reputable research-peptide suppliers typically support each batch with high-performance liquid chromatography (HPLC) data to confirm purity, and mass spectrometry to confirm molecular identity, summarized in a certificate of analysis (COA) tied to a specific lot number. If third-party (independent lab) testing is used, that is stated plainly, since "third-party tested" is a specific claim researchers look for and shouldn't be implied unless accurate.
Specific purity percentages, certifications, or lab names are published only once verified against current documentation.
Helix Bio does not provide reconstitution, dosing, or administration instructions. Any handling beyond storage of the sealed research compound should follow the purchasing institution's own laboratory protocols and be performed by qualified personnel.
Helix Bio ships tesamorelin research orders within the United States. Packaging is intended to help preserve the stability of a lyophilized peptide in transit. Exact shipping timelines, carriers, and packaging materials should be confirmed against Helix Bio's current shipping policy before ordering.
Tesamorelin acetate sold by Helix Bio is intended strictly for laboratory research use by qualified professionals and institutions. It is not a drug, biologic, dietary supplement, food, or cosmetic, and it has not been evaluated or approved by the FDA for human or animal use. This product is not for human consumption, injection, or any form of personal use, and no claims are made regarding safety, efficacy, or suitability for any therapeutic, diagnostic, or performance purpose.
Tesamorelin is also the active ingredient in an FDA-approved prescription medication (Egrifta / Egrifta WR), manufactured by a different company for a specific, physician-prescribed indication. Helix Bio's research-use-only product is not that medication, is not manufactured to pharmaceutical (NDA/BLA) standards, is not interchangeable with it, and this listing makes no comparison of safety or effectiveness between the two. Anyone seeking tesamorelin for a medical purpose should consult a licensed healthcare provider rather than a research chemical supplier.
By purchasing this product, the buyer represents that they are a qualified researcher or are purchasing on behalf of a laboratory or research institution, and that the product will be used solely for legitimate research purposes in compliance with all applicable federal, state, and institutional regulations. Handling, storage, and disposal are the responsibility of the purchasing institution and should follow its own laboratory safety and biosafety protocols. Helix Bio does not provide medical, dosing, or administration advice of any kind.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
What bacteriostatic water contains, how it differs from sterile water and saline, where the 28-day opened-vial figure comes from, and what a COA can show.
Do you need a prescription for peptides? It depends on the category. See which peptides need one, which do not, and the dated 2026 FDA rules that apply.
The complete 2026 list of FDA-approved peptides: 47 drugs by category and approval year, which popular peptides are not approved, and pipeline to watch.
